Browse drugs

…the presence of IL-2/IL-15/IL-21. Each infusion was preceded by cyclophosphamide lymphodepletion and followed by IL-2 support. Clinical response…

…n of CD62L (>96%). Supplementing Synecta T1 with either soluble IL-7 and IL-15 or Synecta CK1 further enhanced expansion, with Synec…

…ltaneous expression of a functional CD19 CAR and membrane bound IL-2 through delivery of two circRNAs. Using a clinical scale protot…

… signal 1 booster construct after 7 days of treatment -/+100 nM rimiducid in the presence of IL-2. (B) Expansion of T cells expressing th…

…g limitations into CNS tumors as they naturally migrate towards CCL2, which is overexpressed in medulloblastoma. Additionally, they …

…itored with cell cultivation in T-VIVO medium supplemented with IL-2 for 7 days. Meanwhile, the transduced T cell function was asses…

…tumors. Six to eight weeks later, mice were lymphodepleted with cyclophosphamide and received TCRMsln-engineered T cells and Msln peptide-pulsed…

…ted with defined cytokine combinations (IL-2, IL-15, IL-18, and IL-21). Cultures were maintained for 10–14 days without media exchang…

…noma. Clin Cancer Res 2021;27(19):5289-5298.Kwong MLM, Yang JC. Lifileucel: FDA-approved T-cell therapy for melanoma. Oncologist 2024;29(8…

…rming successful engraftment and tumor infiltration.Conclusions AGX-148 offers a novel, biomarker selection strategy enriching for tumo…

…solated, activated using CD3/CD28/CD2 stimulants, expanded with IL-2 (1000 IU/mL), and re-infused following a 13-day GMP-compliant e…

…uppression of TRAMP-C2 and RM-1 tumors compared to mSTAR1302 or Olaparib monotherapies. In both models, combination therapy resulted in …